Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
- 30 April 1976
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 192 (4238) , 481-483
- https://doi.org/10.1126/science.3854
Abstract
Tritiated haloperidol and tritiated dopamine label postsynaptic dopamine receptors in mammalian brain. Clinical potencies of butyrophenones, phenothiazines, and related drugs correlate closely with their ability to inhibit tritiated haloperidol binding. These binding methods provide a simple in vitro means for evaluating new drugs as potential antischizophrenic agents.Keywords
This publication has 17 references indexed in Scilit:
- The dopamine receptor: Differential binding of d-LSD and related agents to agonist and antagonist statesLife Sciences, 1975
- Dopamine receptor binding: Differentiation of agonist and antagonist states with 3H-dopamine and 3H-haloperidolLife Sciences, 1975
- Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brainBrain Research, 1975
- Neurotransmitter and drug receptors in the brainBiochemical Pharmacology, 1975
- Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine NeuronsScience, 1975
- The behavioral pharmacology of butaclamol hydrochloride (AY-23,028), a new potent neuroleptic drugPsychopharmacology, 1975
- Drugs, Neurotransmitters, and SchizophreniaScience, 1974
- Membrane ReceptorsAnnual Review of Biochemistry, 1974
- On the excitability and cooperativity of the electroplax membrane.Proceedings of the National Academy of Sciences, 1968
- On the application of “a plausible model” of allosteric proteins to the receptor for acetylcholineJournal of Theoretical Biology, 1967